NRAS and melanoma: With respect to reports on melanoma, Ellerhorst et al[50] reported no difference in patient survival between a group of patients with either BRAF mutation (109 cases) or NRAS mutation (31 cases) and wild-type BRAF/NRAS group (80 cases).